Tesamorelin UK 2026 Research Reference

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

• 1. Overview — tesamorelin’s distinctive position
• 2. Molecular structure — full-length GHRH vs CJC-1295
• 3. GHRH receptor pharmacology
• 4. Pharmacokinetics
• 5. HIV-lipodystrophy pivotal trials
• 6. Visceral fat reduction — magnitude and selectivity
• 7. MASLD and liver fat — emerging data
• 8. Cognitive and CNS research
• 9. IGF-1 dose-response and monitoring
• 10. Pulsatility preservation vs CJC-1295 with DAC
• 11. Safety profile and tolerability
• 12. Reconstitution, storage and stability
• 13. Research protocol design
• 14. UK research-grade sourcing
• FAQ
• References

1. Overview — tesamorelin’s distinctive position

Tesamorelin is the only GHRH analogue with a regulatory approval, giving it a clinical trial evidence base markedly larger than any other growth-hormone-releasing peptide. Its approved indication — reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — reflects the distinctive visceral-fat-reduction effect that has made it a focus of broader cardiometabolic research. Unlike CJC-1295 (based on GHRH 1-29), tesamorelin uses the full-length GHRH 1-44 parent molecule with a single N-terminal modification for DPP-4 resistance. This preserves more of the native GHRH structure and may explain some of the tissue-selectivity differences from CJC-1295.

2. Molecular structure — full-length GHRH vs CJC-1295

Tesamorelin is [trans-3-hexenoyl]-hGHRH(1-44)-NH₂ — the 44-amino-acid native human GHRH sequence with a trans-3-hexenoyl (a C6 unsaturated acyl) group attached to the N-terminal tyrosine. Molecular weight 5196.00 Da. The hexenoyl group blocks DPP-4 cleavage at position 2 (Ala), which would otherwise be the primary inactivation pathway.

Comparison with other GHRH analogues:

• Sermorelin: GHRH(1-29), unmodified, 29 aa. Half-life 10-20 min. No longer widely used.
• CJC-1295 no-DAC: GHRH(1-29) with 4 aa substitutions. Half-life 25-30 min. Preserves pulsatility; supersedes sermorelin.
• CJC-1295 with DAC: Same as no-DAC plus maleimido-lysine tail for albumin conjugation. Half-life ~8 days as albumin conjugate. Tonic activation.
• Tesamorelin: Full-length GHRH(1-44) with hexenoyl N-terminal modification. Half-life ~30-40 min (plasma); biological effect duration 3-4 hours.

The key structural distinction: tesamorelin retains the full C-terminal domain (aa 30-44), which is absent from all CJC-1295 variants. The full-length structure may interact with additional GHRH receptor binding determinants that the 1-29 fragment does not engage, contributing to tesamorelin’s distinctive visceral-fat effect.

3. GHRH receptor pharmacology

Tesamorelin binds and activates the GHRH receptor with similar affinity to native GHRH. Signalling is standard class B GPCR: Gαs → adenylyl cyclase → cAMP → PKA → CREB → GH1 transcription and GH vesicle exocytosis.

A mechanistically relevant point: the GHRH receptor is expressed not only on pituitary somatotrophs but also at lower density on adipose tissue (both SAT and VAT), hepatic cells, and pancreatic cells. Whether direct peripheral GHRHR engagement contributes to tesamorelin’s VAT-selective effect, independent of IGF-1 mediation, is an active research question.

4. Pharmacokinetics

• Plasma half-life: ~26-38 min
• Tmax: 0.5-1 hour after SC injection
• GH releasing effect duration: 3-4 hours
• Bioavailability (SC vs IV): not established directly; clinical dose is based on SC reference
• Steady-state IGF-1 response: reached in 2-4 weeks of daily dosing
• Metabolism: peptide hydrolysis; no CYP involvement
• No clinically meaningful drug interactions identified

5. HIV-lipodystrophy pivotal trials

Tesamorelin was approved on the basis of two pivotal Phase 3 trials (Falutz et al, NEJM 2007; Falutz et al, Lancet 2008) in HIV-infected patients with lipodystrophy and excess abdominal fat:

Study 1 (410 patients, 26 weeks):

• VAT change: tesamorelin 2 mg SC daily −15.2%, placebo −5.0%
• Triglycerides: tesamorelin −50 mg/dL, placebo no change
• IGF-1: tesamorelin +81%, placebo no change
• Waist circumference: tesamorelin −2.2 cm, placebo −0.5 cm

Study 2 (404 patients, 26 weeks):

• VAT change: tesamorelin −10.9%, placebo −0.6%
• Similar lipid and IGF-1 response to Study 1

Extension phase (52 weeks): Patients continued on tesamorelin maintained VAT reductions; patients switched from tesamorelin to placebo regained VAT toward baseline, confirming the effect is treatment-dependent.

6. Visceral fat reduction — magnitude and selectivity

Tesamorelin’s distinctive pharmacological property is its selectivity for visceral (deep abdominal) over subcutaneous adipose tissue. Typical 26-week effects:

• VAT reduction: 15-20% from baseline
• SAT (subcutaneous abdominal fat): minimal change or modest decrease (<5%)
• Total body fat: modest decrease
• Lean mass: modest increase

Mechanism of VAT selectivity: VAT has higher lipolytic tone, greater response to catecholamine and GH signalling, and greater sensitivity to IGF-1 than SAT. Tesamorelin’s elevation of GH pulses and sustained IGF-1 preferentially mobilises VAT stores. Additional direct GHRHR signalling at adipose tissue may contribute.

7. MASLD and liver fat — emerging data

Given the close mechanistic relationship between VAT, hepatic de novo lipogenesis and MASLD, tesamorelin has been investigated in MASLD research:

Stanley et al, Lancet HIV 2019: 61 HIV-infected adults with hepatic steatosis randomised to tesamorelin 2 mg daily vs placebo for 12 months. Results:

• Liver fat fraction (MRS): tesamorelin −0.9% absolute, placebo +0.9% (treatment difference −1.8%)
• Proportion achieving ≥40% relative reduction in hepatic fat: tesamorelin 35%, placebo 4%
• NAS score reduction: tesamorelin, placebo no improvement
• No worsening of fibrosis

This was the first trial to show a GHRH-based therapy reduces liver fat in a MASLD cohort. Magnitude of effect is modest compared to GLP-1 agonists but mechanistically distinct — tesamorelin reduces hepatic de novo lipogenesis directly via IGF-1/GH pathways rather than via weight loss.

8. Cognitive and CNS research

A smaller body of research has examined tesamorelin in cognitive aging and mild cognitive impairment:

Baker et al, Arch Neurol 2012: 20-week tesamorelin trial in 152 adults (mean age 68) with normal cognition or mild cognitive impairment. Modest improvements in executive function and verbal memory domains, attributed to GH/IGF-1 effects on hippocampal and prefrontal function.

This research area remains exploratory but is mechanistically well-grounded: GHRH receptors are expressed in hippocampus, prefrontal cortex and cerebellum, and IGF-1 has established neuroprotective signalling.

9. IGF-1 dose-response and monitoring

Tesamorelin 2 mg daily produces IGF-1 elevation of 50-100% from baseline at steady state. Dose-response:

• 1 mg daily: IGF-1 +30-50%
• 2 mg daily: IGF-1 +50-100% (standard research dose)
• 4 mg daily: IGF-1 +75-120% (rarely used; plateau approaching)

Protocol guidance: measure IGF-1 at baseline, weeks 4, 12 and 26. Target is keeping IGF-1 within the upper half of age-adjusted reference range (typically SDS 0 to +2). Excursion above +2 SDS should trigger dose reduction or dose-frequency reduction.

10. Pulsatility preservation vs CJC-1295 with DAC

Tesamorelin’s ~30-40 minute half-life preserves physiological GH pulsatility when dosed once daily — the GH pulse occurs within the first 1-3 hours post-injection and returns to baseline. This is unlike CJC-1295 with DAC, which produces continuous GHRHR activation.

For research designs where pulsatility is important but longer action than sermorelin or CJC-1295 no-DAC is desired, tesamorelin occupies a useful intermediate pharmacokinetic niche.

11. Safety profile and tolerability

Pooled adverse events from pivotal HIV trials (26-52 weeks):

• Injection-site reactions: 25%
• Arthralgia: 13%
• Peripheral oedema: 6%
• Myalgia: 5%
• Paraesthesia: 5%
• Headache: 5%
• Glucose intolerance: 4% (modest increase in fasting glucose and HbA1c)
• Carpal tunnel syndrome: <3%

Tesamorelin is contraindicated in pregnancy, active malignancy, and in patients with disrupted hypothalamic-pituitary axis function (e.g. history of pituitary surgery, radiation). No cortisol, prolactin or thyroid axis disruption is observed at standard doses.

12. Reconstitution, storage and stability

Tesamorelin ships as lyophilised powder (2 mg/vial typical for research-grade supply). Reconstitute with 2 mL bacteriostatic water → 1 mg/mL. At 2 mg daily, 2 mL per dose (may be split into two 1 mL injections at different sites for tolerability).

Post-reconstitution storage: 2-8°C, use within 30 days. Protect from freezing and light. The full-length GHRH sequence is moderately susceptible to oxidation at the methionine residue; avoid prolonged room-temperature exposure.

13. Research protocol design

Typical UK laboratory research protocols:

• Standard dose: 2 mg SC once daily, consistent timing (typically evening to align with the nocturnal GH pulse)
• Duration: 12-26 week study blocks for VAT or liver-fat endpoints; 4-12 week blocks for IGF-1 dose-response studies
• Primary endpoints: VAT (CT or MRI), liver fat (MRS or MRI-PDFF), IGF-1 AUC
• Secondary endpoints: SAT, triglycerides, HDL-C, fasting glucose, HbA1c, HOMA-IR, waist circumference, lean body mass (DEXA)
• Safety monitoring: IGF-1 every 4-12 weeks with dose adjustment for SDS >+2, glucose and HbA1c every 12 weeks
• Exclusion criteria: pregnancy, active malignancy, pituitary axis disruption, poorly controlled T2DM

14. UK research-grade sourcing

Tesamorelin should be sourced with full documentation:

• ≥98% HPLC purity (≥99% is the emerging 2026 standard)
• Mass spectrometry identity confirmation (theoretical MW 5196.00 Da)
• Batch-specific Certificate of Analysis
• Endotoxin quantification
• Residual TFA analysis
• Lyophilised powder with cold-chain shipping

Quality-control specific note: the trans-3-hexenoyl N-terminal modification is the distinguishing synthetic step. A high-quality COA should specifically address the acylation yield and confirm the absence of des-hexenoyl parent peptide (which would be rapidly DPP-4-inactivated and pharmacologically inactive).

FAQ

Is tesamorelin the same as CJC-1295?
No. CJC-1295 is based on GHRH(1-29); tesamorelin is based on GHRH(1-44). Different molecular weights, different half-lives, different pharmacology. Both are DPP-4-resistant GHRH analogues.

Why is tesamorelin the only approved GHRH analogue?
Regulatory approval followed the pivotal HIV-lipodystrophy trials (2007-2008). No other GHRH analogue has completed an equivalent Phase 3 programme with a primary clinical endpoint.

Does tesamorelin elevate cortisol?
No. GHRH is selective for the GH axis — it stimulates only somatotrophs. Cortisol and prolactin are unaffected.

Why the VAT selectivity?
Combination of (1) greater GH/IGF-1 sensitivity in VAT than SAT and (2) possible direct GHRH-receptor signalling at visceral adipose tissue. The precise mechanistic weighting is an active research question.

Can tesamorelin be combined with ipamorelin?
Mechanistically, yes — same rationale as CJC-1295 + ipamorelin. Synergy on GH pulse amplitude is expected. This combination is less common in the clinical literature than CJC + ipamorelin but is pharmacologically equivalent in concept.

Does tesamorelin work in non-HIV obesity?
VAT reduction appears similar in non-HIV cohorts based on smaller trials, but tesamorelin is not approved for general obesity and is not typically used for whole-body weight loss (GLP-1 agonists are more effective for that).

What’s the relationship to GLP-1 agonists for MASLD?
Complementary. GLP-1 agonists reduce liver fat primarily via weight loss. Tesamorelin reduces liver fat primarily via direct hepatic de novo lipogenesis effects of GH/IGF-1 signalling. Combination research has not been systematically done but is mechanistically rational.

References

1. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359–2370.
2. Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab 2010;95:4291–4304.
3. Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6:e821–e830.
4. Baker LD et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol 2012;69:1420–1429.
5. Ferdinandi ES et al. Nonclinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007;100:49–58.
6. Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res 2015;25:59–65.
7. Adrian S et al. The growth hormone releasing hormone (GHRH) receptor antagonist and GHRH agonist tesamorelin: a review. Endocr Metab Immune Disord Drug Targets 2017;17:66–75.
8. Sinha DK et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition. Transl Androl Urol 2020;9(Suppl 2):S149–S159.
9. Kineman RD et al. Understanding the physiology of growth hormone-releasing hormone and growth hormone-releasing peptide action. Front Endocrinol 2011;2:24.
10. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev 2018;6:45–53.

UK Research Cluster Hubs

• GLP-1 Research Hub
• Tirzepatide Hub
• Retatrutide Hub
• BPC-157 Research Hub
• TB-500 Research Hub
• Growth-Hormone Peptides Hub
• Research-Grade Buyer’s Guide

Disclaimer: All peptides referenced are sold strictly for in vitro laboratory research use. Not for human consumption, veterinary use, food additive, cosmetic, or household purpose. Nothing in this article is medical advice. UK researchers are responsible for compliance with the Human Medicines Regulations 2012 and Misuse of Drugs Regulations 2001 where applicable.